Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aldagen, Inc.
Aldagen IND for stem cell trial to treat critical limb ischemia is cleared by U.S. FDA
May 8th, 2006
Aldagen, Inc., announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to conduct a clinical trial using Aldagen's Aldesort product to isolate a unique stem cell population for therapy for critical limb ischemia patients. It will be the first clinical trial involving this unique cell population for therapy for critical limb ischemia patients in the United States. Critical limb ischemia (CLI) is a severe form of peripheral vascular disease (PVD). It is estimated that between eight to 12 million Americans suffer from PVD, which is a disease of the blood vessels characterized by narrowing and...
Source: Biotech Week (2006-05-08)
|
